Important publication from CADTH regarding optimum use of Iodinated Contrast

The Canadian Agency for Drugs and Technologies in Health, or CADTH, is a Canadian national organisation that provides research and analysis to healthcare decision-makers.

CADTH has released a review document:  Optimizing the Use of ICM for CT: Managing Shortages and Planning for a Sustainable and Secure Supply.

This report summarizes information identified through a limited literature search using PubMed and grey literature sources of information. 

The summary includes all clinical guidance developed on the national, provincial, regional, and institutional levels that helped risk mitigate during the shortage. 

The experience we gained during the shortage can now be used to manage the utilization of contrast on an ongoing basis.

Updated April 6, 2023